{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T20:21:56Z","timestamp":1794514916191,"version":"4.9.1"},"reference-count":39,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Serious or severe hypersensitivity reactions (HSRs) are uncommon with modern IV iron formulations but, when occurring, can be life-threatening or even fatal. We synthesized available data on incidence of serious or severe HSR for ferric derisomaltose (FDI), ferric carboxymaltose (FCM), and ferumoxytol (FER) as treatments for iron deficiency anemia. A systematic literature review for randomized controlled trials (RCTs) was conducted in PubMed, Embase, and Cochrane Central Register of Controlled Trials. From eligible RCTs, proportions of patients experiencing serious or severe HSR after IV iron administration, reported using the Standardized Medical Dictionary for Regulatory Activities Query (SMQ) for anaphylactic reaction, were extracted. A Bayesian random-effects model was used to obtain posterior distributions of HSR incidence and surface under the cumulative ranking curve (SUCRA) plots, ranking formulations by HSR likelihood. Any serious or severe HSR falling under the anaphylactic reaction SMQ was experienced by 0.14% of patients receiving FDI, 0.59% of patients receiving FCM, and 0.50% of patients receiving FER. The meta-analysis indicated a reduced serious or severe HSR risk with FDI vs FCM (0.21; 95% credible interval [CrI], 0.03-1.73) and FER (0.07; 95% CrI, 0.00-1.93). SUCRA plots showed that the likelihood of FDI having the lowest serious or severe HSR incidence was 91.4% (FCM, 4.5%; FER, 4.2%). This meta-analysis of data from RCTs, including 11\u2009268 patients, represents a comprehensive analysis of serious or severe HSRs among available high-dose, rapid-infusion IV iron formulations, detailing an important facet of formulation safety profiles.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026019945","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:41:10Z","timestamp":1789573270000},"page":"7536-7542","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Systematic review and meta-analysis of hypersensitivity reactions after high-dose IV iron"],"prefix":"10.1182","volume":"10","author":[{"given":"Stephen","family":"Divers","sequence":"first","affiliation":[{"name":"1Genesis Cancer and Blood Institute, Hot Springs, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Elder","sequence":"additional","affiliation":[{"name":"2Florida Cancer Specialists & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9264-4393","authenticated-orcid":false,"given":"Patrick C.","family":"Foy","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9123-8107","authenticated-orcid":false,"given":"Jason A.","family":"Freed","sequence":"additional","affiliation":[{"name":"4Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Peters","sequence":"additional","affiliation":[{"name":"5American Oncology Network, Fort Myers, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-755X","authenticated-orcid":false,"given":"Johannes","family":"P\u00f6hlmann","sequence":"additional","affiliation":[{"name":"6Covalence Research, Harpenden, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9873-7507","authenticated-orcid":false,"given":"Richard F.","family":"Pollock","sequence":"additional","affiliation":[{"name":"6Covalence Research, Harpenden, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2026111214365663200_bib1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/ph11030082","article-title":"Intravenous irons: from basic science to clinical practice","volume":"11","author":"Bhandari","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9","key":"2026111214365663200_bib2","doi-asserted-by":"crossref","first-page":"e713","DOI":"10.1016\/S2352-3026(23)00160-6","article-title":"Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990-2021: findings from the Global Burden of Disease Study 2021","volume":"10","author":"GBD 2021 Anaemia Collaborators","year":"2023","journal-title":"Lancet Haematol"},{"issue":"2","key":"2026111214365663200_bib3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.7861\/clinmed.2020-0582","article-title":"Iron deficiency without anaemia: a diagnosis that matters","volume":"21","author":"Al-Naseem","year":"2021","journal-title":"Clin Med (Lond)"},{"issue":"2","key":"2026111214365663200_bib4","first-page":"137","article-title":"Prevention and management of acute reactions to intravenous iron in surgical patients","volume":"17","author":"G\u00f3mez-Ram\u00edrez","year":"2019","journal-title":"Blood Transfus"},{"issue":"6","key":"2026111214365663200_bib5","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/trf.15837","article-title":"Clinical data for intravenous iron - debunking the hype around hypersensitivity","volume":"60","author":"Achebe","year":"2020","journal-title":"Transfusion"},{"issue":"7","key":"2026111214365663200_bib6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/14740338.2021.1912010","article-title":"Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular safety","volume":"20","author":"Blumenstein","year":"2021","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"2026111214365663200_bib7","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"2026111214365663200_bib8","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ajh.25060","article-title":"Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial","volume":"93","author":"Adkinson","year":"2018","journal-title":"Am J Hematol"},{"issue":"9","key":"2026111214365663200_bib9","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/ajh.25564","article-title":"A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial","volume":"94","author":"Auerbach","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"2026111214365663200_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfaa011","article-title":"Safety and efficacy of iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial","volume":"36","author":"Bhandari","year":"2021","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"2026111214365663200_bib11","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/ajh.26015","article-title":"Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: the FERWON-IDA\/NEPHRO trials","volume":"96","author":"Wolf","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"2026111214365663200_bib36","doi-asserted-by":"crossref","first-page":"52","DOI":"10.33696\/haematology.5.061","article-title":"Comparison of healthcare resource utilization, cost of care, and health outcomes associated with different intravenous iron products in heart failure patients with iron deficiency\/iron deficiency anemia: a claims database analysis","volume":"5","author":"Wang","year":"2025","journal-title":"J Clin Haematol"},{"issue":"suppl 1","key":"2026111214365663200_bib37","article-title":"Ferric derisomaltose achieves highest likelihood of \u22651000-mg dose administered and lowest outpatient transfusion rates among intravenous iron therapies in women with iron deficiency anemia and abnormal uterine bleeding: a real-world analysis","volume":"1","author":"von Drygalski","year":"2026","journal-title":"NCODA"},{"issue":"12","key":"2026111214365663200_bib38","first-page":"516","article-title":"Payment incentives and the use of higher-cost drugs: a retrospective cohort analysis of intravenous iron in the Medicare population","volume":"26","author":"Hambley","year":"2020","journal-title":"Am J Manag Care"},{"issue":"10","key":"2026111214365663200_bib12","first-page":"1473","article-title":"Hypersensitivity to intravenous iron preparations","volume":"9","author":"Caimmi","year":"2022","journal-title":"Children (Basel)"},{"issue":"21","key":"2026111214365663200_bib13","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1111\/bph.13268","article-title":"Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management","volume":"172","author":"Szebeni","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"10","key":"2026111214365663200_bib14","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/pds.5319","article-title":"Use of intravenous iron and risk of anaphylaxis: a multinational observational post-authorisation safety study in Europe","volume":"30","author":"Fortuny","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026111214365663200_bib15","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.3389\/fimmu.2019.01885","article-title":"Administration of intravenous iron formulations induces complement activation in-vivo","volume":"10","author":"Faria","year":"2019","journal-title":"Front Immunol"},{"issue":"7","key":"2026111214365663200_bib16","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/ajh.27220","article-title":"Expert consensus guidelines: intravenous iron uses, formulations, administration, and management of reactions","volume":"99","author":"Van Doren","year":"2024","journal-title":"Am J Hematol"},{"issue":"3","key":"2026111214365663200_bib17","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ejpb.2011.03.016","article-title":"A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications","volume":"78","author":"Jahn","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"2026111214365663200_bib18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/asheducation-2016.1.57","article-title":"Single-dose intravenous iron for iron deficiency: a new paradigm","volume":"2016","author":"Auerbach","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"11","key":"2026111214365663200_bib19","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3324\/haematol.2014.111492","article-title":"Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management","volume":"99","author":"Rampton","year":"2014","journal-title":"Haematologica"},{"issue":"12","key":"2026111214365663200_bib20","doi-asserted-by":"crossref","first-page":"E496","DOI":"10.1002\/ajh.24531","article-title":"Reports to FDA of fatal anaphylaxis associated with intravenous iron products","volume":"91","author":"McCulley","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"2026111214365663200_bib21","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1182\/hematology.2023000495","article-title":"IV iron formulations and use in adults","volume":"2023","author":"Van Doren","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"2026111214365663200_bib22","doi-asserted-by":"crossref","first-page":"e224488","DOI":"10.1001\/jamanetworkopen.2022.4488","article-title":"Analysis of adverse events and intravenous iron infusion formulations in adults with and without prior infusion reactions","volume":"5","author":"Arastu","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2026111214365663200_bib23","doi-asserted-by":"crossref","first-page":"e70191","DOI":"10.1002\/nop2.70191","article-title":"Understanding and managing infusion reactions and hypophosphataemia with intravenous iron - a nurses\u2019 consensus paper","volume":"12","author":"Fraser","year":"2025","journal-title":"Nurs Open"},{"issue":"1","key":"2026111214365663200_bib24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.mayocp.2014.10.007","article-title":"The safety of intravenous iron preparations: systematic review and meta-analysis","volume":"90","author":"Avni","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2026111214365663200_bib25","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s11096-023-01548-2","article-title":"A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose","volume":"45","author":"Kennedy","year":"2023","journal-title":"Int J Clin Pharm"},{"key":"2026111214365663200_bib39","unstructured":"AbbVie\n          . INFeD (iron dextran injection), for intravenous or intramuscular use: highlights of prescribing information. Accessed 1 September 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/017441s181lbl.pdf."},{"key":"2026111214365663200_bib26","unstructured":"Pollock\n              RF\n            , DiversS, ElderC, FoyP, PetersB, P\u00f6hlmannJ. A Systematic Literature Review and Meta-Analysis of Hypersensitivity Reactions After Administration of Ferumoxytol, Ferric Derisomaltose and Ferric Carboxymaltose In Patients With Iron Deficiency Anemia. Accessed 2 June 2026. https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251068759."},{"issue":"1","key":"2026111214365663200_bib27","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12874-019-0829-2","article-title":"BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network meta-analyses","volume":"19","author":"B\u00e9liveau","year":"2019","journal-title":"BMC Med Res Methodol"},{"issue":"9-10","key":"2026111214365663200_bib28","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/sim.4780140924","article-title":"Bayesian predictive approach for inference about proportions","volume":"14","author":"Lecoutre","year":"1995","journal-title":"Stat Med"},{"key":"2026111214365663200_bib29","author":"Grant","year":"2025","edition":"1st ed"},{"issue":"5","key":"2026111214365663200_bib30","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/aje\/kwab278","article-title":"Introducing the treatment hierarchy question in network meta-analysis","volume":"191","author":"Salanti","year":"2022","journal-title":"Am J Epidemiol"},{"issue":"4","key":"2026111214365663200_bib31","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/gutjnl-2022-327897","article-title":"Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial","volume":"72","author":"Zoller","year":"2023","journal-title":"Gut"},{"issue":"4","key":"2026111214365663200_bib32","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00404-022-06768-x","article-title":"Intravenous ferric derisomaltose versus oral iron for persistent iron deficient pregnant women: a randomised controlled trial","volume":"308","author":"Hansen","year":"2023","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"2026111214365663200_bib33","doi-asserted-by":"crossref","first-page":"120.e1","DOI":"10.1016\/j.ajog.2025.01.037","article-title":"Single-dose intravenous iron vs oral iron for treatment of maternal iron deficiency anemia: a randomized clinical trial","volume":"233","author":"Derman","year":"2025","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"2026111214365663200_bib34","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1016\/S2352-3026(25)00038-9","article-title":"Management of iron deficiency in children, adults, and pregnant individuals: evidence-based and expert consensus recommendations","volume":"12","author":"Benson","year":"2025","journal-title":"Lancet Haematol"},{"issue":"3","key":"2026111214365663200_bib35","first-page":"296","article-title":"Safety of intravenous iron formulations: facts and folklore","volume":"12","author":"Auerbach","year":"2014","journal-title":"Blood Transfus"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/22\/7536\/2600068\/blooda_adv-2026-019945-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/22\/7536\/2600068\/blooda_adv-2026-019945-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:37:11Z","timestamp":1794512231000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/22\/7536\/570967\/Systematic-review-and-meta-analysis-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,24]]},"references-count":39,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2026,11,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026019945","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11,24]]},"published":{"date-parts":[[2026,11,24]]}}}